ClinicalTrials.gg
CompletedNCT03116152Updated Feb 3, 2021Results posted

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

A Phase 2 interventional study of IBI308 and paclitaxel/ irinotecan in Esophageal Squamous Cell Carcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma — 9 open to participants now, 9 under way, 4 of them phase 3. sintilimab · Esophageal Squamous Cell Carcinoma.

Enrollment
5th of 21
190 · median 52
Started
2017
the only one that year
Phase 2
14 of 21
5 open now
Registered
1st of 21
by date
Lead sponsor
2 of 21
Innovent Biologics (Suzhou) Co. Ltd.

Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 14 in phase 2, and was the 1st registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

9 of the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study

Read the detailed description

Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study (ORIENT-2)

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed locally advanced unresectable or esophageal squamous cell carcinoma (excluding mixed adenosquamous carcinoma and other pathological types).
  2. Imaging evidence (e.g. CT scan) or clinical evidence (e.g. cytological report of new ascites or pleural effusion) of disease progression during or after chemotherapy; Subjects have to receive at least one dose of first-line treatment, permitting discontinuation or dose reduction of one drug or exchange of fluorouracil drugs used during first-line treatment, and patients discontinuing first-line treatment due to intolerable toxicity are allowed to be enrolled; or adjuvant therapy (chemotherapy or chemo-radiotherapy) should be regarded as first-line treatment if there is disease progression during treatment or within 6 months after treatment discontinuation.
  3. At least one according to v1.1.
  4. PS score of 0 or 1.
  5. Subjects who have signed the written form and are able to follow the visit schedule and relevant procedures as specified in the study protocol.
  6. Age ≥ 18 and ≤ 75 years.
  7. ≥ 12 weeks.
  8. Female subjects of or male subjects with sexual partners of childbearing potential should use effective throughout and within 6 months after treatment.
  9. Adequate organ and bone marrow functions, defined as follows:

    • Hematology: (ANC) ≥ 1.5×10\^9/L; (PLT) count ≥ 100×10\^9/L; (HGB) ≥ 9.0 g/dL.
    • Liver function: serum total (TBIL) ≤ 1.5× (ULN); (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum albumin ≥ 28 g/L.
    • Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN, or (Ccr) ≥ 40 mL/min (calculated using the standard Cockcroft -Gault formula):

      • Females: CrCl = (140-age) x body weight (kg) x 0.85/(72 x serum creatinine (mg/dL))
      • Males: CrCl = (140-age) x body weight (kg) x 1.00/(72 x serum creatinine (mg/dL))

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to any or anti-PD-L1 antibody.
  2. Concurrent participation in another interventional clinical study, except for observational (non-interventional) clinical studies or in the follow-up phase of an interventional study.
  3. Receipt of any products within 4 weeks prior to the first dose of study treatment.
  4. Receipt of the last dose of anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy, tumor embolization) within 3 weeks prior to the first dose of study treatment.
  5. Radiotherapy within 4 weeks prior to the first dose of study treatment.
  6. Receipt of agents within 4 weeks prior to the first dose of study treatment, excluding topical for intranasal, inhalation or other routes of administration, or physiological doses of systemic glucocorticoids (i.e., no more than 10 mg/day prednisone or equivalent doses of other glucocorticoids).
  7. Receipt of a within 4 weeks prior to the first dose of study treatment or planned receipt of a live attenuated vaccine during the study.
  8. Subjects who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first dose of study treatment or have unhealed wound, ulcers or bone fracture.
  9. Presence of toxicities induced by previous anti-tumor therapy that have not recovered to Grade 0 or 1 as assessed per 4.03 (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03) prior to the first dose of study treatment, excluding alopecia, and non- and asymptomatic laboratory abnormalities.
  10. Known symptomatic to central nervous system (CNS) and/or carcinomatous meningitis. Subjects previously treated for are eligible for the study provided the brain metastasis has remained stable for at least 4 weeks before first dose of study treatment; Neurological symptoms must be recovered to grade 0 or 1 as per NCI CTCAE version 4.03.
  11. Active, known or suspected diseases (refer to Appendix 6) or a history of such disease in the past 2 years (patients with vitiligo, psoriasis, alopecia or Grave's disease requiring no systemic treatment in the past 2 years, patients with hypothyroidism requiring only thyroid hormone replacement therapy and patients with type I diabetes requiring only insulin replacement therapy can be enrolled).
  12. Known history of primary immunodeficiency.
  13. Known active tuberculosis (TB).
  14. Known history of allotransplantation and hematopoietic stem cell transplantation.
  15. Known to any component of the monoclonal antibody, paclitaxel or irinotecan formulation.
  16. Uncontrolled concurrent diseases, including but not limited to:

    • infection (HIV antibody positive).
    • Active or clinically uncontrolled severe infections.
    • Symptomatic congestive heart failure ( Class II-IV) or symptomatic or poorly controlled arrhythmia.
    • Uncontrolled arterial hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite standard treatment.
    • Any arterial thromboembolism events within 6 months prior to inclusion for treatment, including myocardial infarction, unstable angina, cerebrovascular accident or .
    • Significant malnutrition, if intravenous nutrient solution supplement is required; Except for malnutrition corrected for more than 4 weeks before first dose of study treatment.
    • Tumor invasion into surrounding vital organs (e.g., aorta and trachea) or a risk for esophagotracheal fistula or esophagopleural fistula.
    • Post esophageal or intratracheal stenting.
    • History of deep vein thrombosis (DVT), pulmonary embolism, or any other serious thromboembolism within 3 months prior to enrollment (implanted venous access port or catheter-related thrombosis, or superficial venous thrombosis is not considered as "serious"thromboembolism).
    • Uncontrolled metabolic disorders or other non-malignant organic or systemic diseases or reactions secondary to cancer, which can result in high medical risks and/or uncertainty in survival evaluations.
    • Hepatic encephalopathy, hepatorenal syndrome, or class B or even more severe cirrhosis.
    • History of intestinal obstruction or the following diseases: inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive resection of the small intestine, concurrent chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
    • Other acute or chronic diseases, mental disorders or abnormal laboratory findings that may lead to the following results: increase risks associated with study participation in the study or use of the study drug, or interfere with the interpretation of study results, and render the patient ineligible for the study at the investigator's discretion.
  17. Known acute or chronic active (HBsAg positive and HBV DNA ≥200 IU/mL or ≥ 10\^3 copies/mL) or acute or chronic active (HCV antibody positive and positive for HCV RNA test).
  18. History of gastrointestinal perforation and/or fistula within 6 months prior to study inclusion.
  19. Presence of interstitial lung disease.
  20. Clinically uncontrollable effusion of the third space, such as pleural effusion and ascites that can not be controlled by drainage or other methods before enrollment.
  21. History of other primary , excluding:

    • A malignancy with complete remission for at least 2 years before enrollment and requiring no other treatment during the study;
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of relapse;
    • Adequately treated carcinoma in situ without evidence of relapse.
  22. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    IBI308

    IBI308 200mg Intravenous drip every three weeks

    Biological: IBI308

  • Active comparator
    paclitaxel/irinotecan

    paclitaxel 175mg/㎡ Intravenous drip every three weeks; irinotecan 180mg/㎡ Intravenous drip every two weeks

    Drug: paclitaxel/ irinotecan

Interventions

  • BiologicalIBI308

    IBI308 200mg Intravenous drip every three weeks;

  • Drugpaclitaxel/ irinotecan

    Drug pages: Paclitaxel · Irinotecan

    paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks

06

What researchers measure

Primary outcomes

  1. Overall Survival

    OS was defined as the time from randomization to death due to any cause. Median OS in all participants is presented.

    Time frame: Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)

Secondary outcomes

  1. Progression-free Survival

    PFS was defined as the time from randomization to the first documented progressive disease (PD) as determined by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Unequivocal progression of non-target leisions and the appearance of ≥1 new lesions were also considered as PD.

    Time frame: Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)

  2. Objective Response Rate

    Objective Response Rate (ORR) was defined as the proportion of randomized participants who achieved a best response of complete response (CR) or partial response (PR) using the RECIST1.1 criteria as per investigator assessment.

    Time frame: Through Final Analysis data cut-off date of 2-August-2019 (up to approximately 26 months)

  3. Duration of Response

    Duration of response (DoR) was defined as the time from the date of the first investigator-assessed response (CR or PR) to the date of subsequent investigator-assessed PD or death, whichever is earlier.

    Time frame: Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)

07

Results

Posted Jan 19, 2021

Participant flow

Participant flow — Overall Study
MilestoneSintilimabChemotherapy
Started9595
Treated9487
Completed40
Not completed9195
Withdrew: Disease progression4947
Withdrew: Death52
Withdrew: Adverse event217
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject01
Withdrew: Physician decision32
Withdrew: Other1134

Outcome measures

PrimaryOverall Survival

OS was defined as the time from randomization to death due to any cause. Median OS in all participants is presented.

Time frame:
Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)
Reported as:
Median · month
Overall Survival
monthSintilimabChemotherapy
Overall Survival7.23 (5.82 to 9.69)6.21 (5.39 to 7.85)
Statistical analysis
  • Sintilimab vs Chemotherapy · Log Rank · p = 0.032 · Hazard ratio (hr): 0.701 · 95% CI 0.504 to 0.972
SecondaryProgression-free Survival

PFS was defined as the time from randomization to the first documented progressive disease (PD) as determined by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Unequivocal progression of non-target leisions and the appearance of ≥1 new lesions were also considered as PD.

Time frame:
Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)
Reported as:
Median · month
Progression-free Survival
monthSintilimabChemotherapy
Progression-free Survival1.58 (1.45 to 2.76)2.86 (2.56 to 3.55)
Statistical analysis
  • Sintilimab vs Chemotherapy · Log Rank · p = 0.979 · Hazard ratio (hr): 1.002 · 95% CI 0.722 to 1.391
SecondaryObjective Response Rate

Objective Response Rate (ORR) was defined as the proportion of randomized participants who achieved a best response of complete response (CR) or partial response (PR) using the RECIST1.1 criteria as per investigator assessment.

Time frame:
Through Final Analysis data cut-off date of 2-August-2019 (up to approximately 26 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsSintilimabChemotherapy
Objective Response Rate12.6 (6.7 to 21.0)6.3 (2.4 to 13.2)
Statistical analysis
  • Sintilimab vs Chemotherapy · Difference in percentages: 6.3 · 95% CI -2.2 to 15.4
SecondaryDuration of Response

Duration of response (DoR) was defined as the time from the date of the first investigator-assessed response (CR or PR) to the date of subsequent investigator-assessed PD or death, whichever is earlier.

Time frame:
Through Final Analysis data cutoff date of 2-August-2019 (up to approximately 26 months)
Reported as:
Median · month
Duration of Response
monthSintilimabChemotherapy
Duration of Response8.28 (2.92 to 20.9)6.21 (4.57 to 8.38)
Statistical analysis
  • Sintilimab vs Chemotherapy · Log Rank · p = 0.345

Adverse events

Collected over Through the Analysis data cutoff date of 2-October-2019 (up to approximately 26 months). The cutoff date for the primary efficacy analysis was 02 August 2019 when 150 OS events were actually observed. Upon the observation, the study follow-up was extended for another 2 months. The safety data was cut off as of 2-October-2019. AEs were collected till 90 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sintilimab73/95 (76.8%)41/94 (43.6%)88/94 (93.6%)
Chemotherapy82/95 (86.3%)23/87 (26.4%)78/87 (89.7%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventSintilimabChemotherapy
Bone marrow failureBlood and lymphatic system disorders0/946/87
PneumoniaInfections and infestations6/940/87
PneumonitisRespiratory, thoracic and mediastinal disorders6/940/87
Upper gastrointestinal haemorrhageGastrointestinal disorders5/941/87
Lung infectionInfections and infestations5/944/87
Hepatic function abnormalHepatobiliary disorders4/940/87
DiarrhoeaGastrointestinal disorders0/942/87
Acquired tracheo-oesophageal fistulaRespiratory, thoracic and mediastinal disorders1/942/87
DysphagiaGastrointestinal disorders2/940/87
Gastrointestinal haemorrhageGastrointestinal disorders2/940/87
Most frequent other events
Showing 10 of 47
Most frequent other events
EventSintilimabChemotherapy
White blood cell count decreasedInvestigations13/9445/87
AnaemiaBlood and lymphatic system disorders46/9443/87
Neutrophil count decreasedInvestigations10/9432/87
DiarrhoeaGastrointestinal disorders12/9432/87
NauseaGastrointestinal disorders12/9431/87
Weight decreasedInvestigations28/9415/87
AstheniaGeneral disorders16/9423/87
HypoproteinaemiaMetabolism and nutrition disorders23/948/87
CoughRespiratory, thoracic and mediastinal disorders23/947/87
VomitingGastrointestinal disorders12/9421/87

Baseline characteristics

All randomized participants

Age, Categorical
Age, Categorical(Participants)SintilimabChemotherapyTotal
<=18 years000
Between 18 and 65 years7475149
>=65 years212041
Age, Continuous
Age, Continuous(years)SintilimabChemotherapyTotal
Mean58.8 ± 7.2359.4 ± 7.0659.1 ± 7.13
Sex: Female, Male
Sex: Female, Male(Participants)SintilimabChemotherapyTotal
Female71118
Male8884172
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SintilimabChemotherapyTotal
American Indian or Alaska Native000
Asian9595190
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)SintilimabChemotherapyTotal
China9595190
08

Study locations

1 site
  • The Fifth Medical Center of PLA Ceneral Hospital
    Beijing, Beijing 10071, China
09

References and documents

Publications

  • Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. PubMed 35165274 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Oct 2019, 28 months.

Results were first posted in Jan 2021, 1 year 3 months after primary completion.

Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2017
First posted
Apr 14, 2017
StartActual
May 10, 2017
Primary completionActual
Oct 2, 2019
CompletionActual
Oct 2, 2019
Results first posted
Jan 19, 2021
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03116152
Responsible party
Sponsor
First posted
Apr 14, 2017
Start date
May 10, 2017
Primary completion
Oct 2, 2019
Completion
Oct 2, 2019
Results posted
Jan 19, 2021
Last update
Feb 3, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion